Department of Orthopedics and Rheumatology, University Hospital Marburg, Baldingerstrasse, 35043 Marburg, Germany.
Osteoarthritis Cartilage. 2010 Jun;18(6):849-56. doi: 10.1016/j.joca.2010.02.007. Epub 2010 Feb 18.
Recent studies have shown abnormal expression of CD44s and some of its isoforms in many human malignancies, but little is known about the presence of CD44 in chondrosarcoma. In this study the expression of CD44s and two variant isoforms was evaluated. It was assumed that abnormalities in these receptor proteins may be associated with clinical outcome of the patients.
Thirty paraffin-embedded chondrosarcoma samples were immunostained with monoclonal antibodies for CD44s, CD44v5 and CD44v6. Two independent examiners who were unaware of the clinical status of the patients evaluated the immunohistochemical results. The percentage of CD44-positive cells was scored semiquantitatively. A rate of higher than 10% was considered as overexpression.
Among the 30 patients (median age 50 years) there were 22 conventional chondrosarcomas, two dedifferentiated chondrosarcomas, two extraskeletal chondrosarcomas, and one periostal, mesenchymal, clear cell and myxoid chondrosarcoma each. In the immunochemistry staining overexpression (>10% of cells) of CD44s was shown in 56.7% (17 of 30), of CD44v5 in 43.3% (13 of 30) and of CD44v6 in 6.7% (two of 30) of the tumors. Four grade III chondrosarcomas (80%) and 10 (71.4%) grade II chondrosarcomas showed overexpression for CD44s, whereas CD44s was overexpressed in only three (27.3%) grade I chondrosarcomas. Cox regression suggests overexpression of CD44s to be an additional prognostic marker for chondroid bone tumors independent of grading and other covariates.
Overexpression of CD44s correlated significantly with metastatic potential and with poorer survival in patients with chondrosarcoma. CD44s might be an independent additional marker, but small sample size remains to be considered.
最近的研究表明，CD44s 及其一些同工型在许多人类恶性肿瘤中表达异常，但关于软骨肉瘤中 CD44 的存在知之甚少。本研究评估了 CD44s 和两种变体同工型的表达。假设这些受体蛋白的异常可能与患者的临床结果有关。
对 30 例石蜡包埋的软骨肉瘤样本进行 CD44s、CD44v5 和 CD44v6 的单克隆抗体免疫染色。两位对患者临床状况不知情的独立检查者评估了免疫组织化学结果。CD44 阳性细胞的百分比进行半定量评分。超过 10%的比例被认为是过表达。
在 30 名患者（中位年龄 50 岁）中，有 22 例常规软骨肉瘤、2 例去分化软骨肉瘤、2 例骨外软骨肉瘤、1 例骨膜、间充质、透明细胞和粘液样软骨肉瘤。在免疫化学染色中，CD44s 的过表达（>10%的细胞）在 56.7%（30 例中的 17 例）、CD44v5 在 43.3%（30 例中的 13 例）和 CD44v6 在 6.7%（30 例中的 2 例）的肿瘤中显示。4 例 3 级软骨肉瘤（80%）和 10 例 2 级软骨肉瘤（71.4%）CD44s 过表达，而 1 级软骨肉瘤中只有 3 例（27.3%）过表达 CD44s。Cox 回归表明，CD44s 的过表达是软骨源性骨肿瘤的独立预后标志物，与分级和其他协变量无关。
CD44s 的过表达与软骨肉瘤患者的转移潜力和生存预后不良显著相关。CD44s 可能是一个独立的附加标志物，但样本量小仍需考虑。
